| __timestamp | Bristol-Myers Squibb Company | Cytokinetics, Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 5699000000 | 17268000 |
| Thursday, January 1, 2015 | 5001000000 | 19667000 |
| Friday, January 1, 2016 | 5002000000 | 27823000 |
| Sunday, January 1, 2017 | 4849000000 | 36468000 |
| Monday, January 1, 2018 | 4551000000 | 31282000 |
| Tuesday, January 1, 2019 | 4871000000 | 39610000 |
| Wednesday, January 1, 2020 | 7661000000 | 52820000 |
| Friday, January 1, 2021 | 7690000000 | 96803000 |
| Saturday, January 1, 2022 | 7814000000 | 177977000 |
| Sunday, January 1, 2023 | 7772000000 | 173612000 |
| Monday, January 1, 2024 | 8414000000 |
Unleashing insights
In the competitive landscape of the pharmaceutical industry, understanding spending patterns can offer valuable insights into a company's strategic priorities. Bristol-Myers Squibb Company, a global biopharmaceutical giant, and Cytokinetics, Incorporated, a smaller biotech firm, present a fascinating contrast in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Bristol-Myers Squibb's SG&A expenses have shown a steady increase, peaking in 2022 with a 37% rise from 2014. This trend reflects their expansive market strategies and robust operational scale. In contrast, Cytokinetics, while significantly smaller in scale, has seen its SG&A expenses grow by over 900% during the same period, indicating aggressive investment in growth and development.
These spending patterns highlight the differing strategies of established versus emerging players in the pharmaceutical sector, offering a window into their future trajectories.
Operational Costs Compared: SG&A Analysis of Johnson & Johnson and Bristol-Myers Squibb Company
Bristol-Myers Squibb Company or Zoetis Inc.: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Bristol-Myers Squibb Company vs Neurocrine Biosciences, Inc.
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? Bristol-Myers Squibb Company or Taro Pharmaceutical Industries Ltd.
Alnylam Pharmaceuticals, Inc. vs Cytokinetics, Incorporated: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for BeiGene, Ltd. and Cytokinetics, Incorporated
Selling, General, and Administrative Costs: Catalent, Inc. vs Cytokinetics, Incorporated
Operational Costs Compared: SG&A Analysis of Cytokinetics, Incorporated and Soleno Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Geron Corporation
Cytokinetics, Incorporated or Celldex Therapeutics, Inc.: Who Manages SG&A Costs Better?